Six Percent Growth, Sold: The Telegraphed Trough Quarter Arrives and the Street Reads the FY27 Footnotes — Maintain Outperform

Results vs. Consensus

Q3 FY2026 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Quality of Beat

Revenue: the third consecutive quarter of organic acceleration (4.8% → 5.5% → 6.0%), and the first where the breadth matched the headline. Cardiovascular grew 10.6% organic with the U.S. at 13%; CRM — still 15% of company revenue — grew 5%; Peripheral Vascular Health reached high-single digits; Endoscopy grew 10%; ACM grew 7%; Diabetes grew 8.3% with a U.S. sequential inflection as the December sensor launches converted the order backlog. Geographic balance held (Western Europe high-single, U.S. 6%, Japan mid-single, China low-single but mid-single ex-VBP). The two soft spots — Neuroscience at 2.5% organic and Structural Heart at low-single — both carry named, dated fixes (Stealth AXiS contribution from Q4; Anteris/portfolio actions).

Margins: the −170bp gross margin decline decomposes into tariffs (−110bp, $93M, in line with forecast), mix (−100bp, peak CAS-capital and Simplera-ramp drag), pricing (+30bp, third consecutive quarter), cost-down net of inflation (−20bp, seasonally weakest quarter plus prior-year non-recurring items), and FX (+40bp). Nothing in the bridge is new information — every component was either pre-announced in November or is the mechanical result of growth mix. The forward-looking change is mildly positive: full-year gross margin guidance improved to −~30bp including tariffs (from −~40bp), and SG&A delivered the promised H2 leverage (32.3% of revenue, −30bp YoY) even while funding three launches.

EPS: $1.36, flat sequentially, down 2% YoY — the first YoY adjusted EPS decline of the fiscal year, fully attributable to the tariff/mix concentration plus a tax rate ~100bp worse than forecast on jurisdictional mix. The beat versus guide was revenue-driven (CRM, ACM), which management explicitly declined to extrapolate. We'd note what didn't happen: no reserve releases, no buyback acceleration, no below-the-line gymnastics to manufacture a YoY increase. The willingness to print a down-EPS quarter while reiterating the FY27 high-single-digit commitment is itself information about how management is managing the transition year.

Segment Performance

Portfolio Revenue Mix — Q3 FY2026

Cardiovascular — 11% Growth and a Share-Gain Scoreboard

Cardiovascular delivered 11% growth (13% in the U.S.) — its strongest in a decade excluding COVID comps — for the second consecutive quarter of decade-best framing. CAS grew 80% with PFA now 80% of CAS revenue and worldwide PFA up nearly 200%; management claimed four points of share gain in a market it now sizes at $13B+ growing ~20%. The versatility argument for Sphere-9 sharpened with a striking utilization disclosure: 50–60% of cases now use both PFA and RF energies through the single catheter with integrated mapping. CRM grew 5% on double-digit Micra, mid-teens 3830 conduction-system leads, and 70%+ EV-ICD growth. Peripheral Vascular Health grew high-single digits on the endoVenous portfolio with NeuroGuard and Liberant still ramping. Structural Heart was the drag: low-single-digit growth, with international share gains offset by U.S. competitive pressure as the Evolut FX+ launch annualized.

"With 80% growth year-over-year, our Cardiac Ablation Solutions business was once again the fastest growing in the segment, doubling the growth rate of our closest competitor… we remain on track to double our revenue in this business, delivering $2 billion trailing in total CAS revenue by first half of fiscal year '27." — Geoff Martha, Chairman & CEO

Assessment: the $2B-by-1H-FY27 commitment now has a date attached, and the math requires CAS to sustain roughly its current growth rate for two to three more quarters — aggressive but consistent with the installed-base trajectory and the Sphere-360 European commercialization starting this spring. Structural Heart's U.S. pressure is the segment's real issue: TAVR is a two-player U.S. market where the competitor is executing well, and Medtronic's response (Anteris balloon-expandable optionality, mitral/tricuspid programs) is a multi-year fix, not a next-quarter one.

Neuroscience — A Miss With a Catalyst Attached

Neuroscience grew 2.5% organic, below management's own expectations and the portfolio's weakest print. CST grew mid-single digits with 8% Core Spine pull-through; Neuromodulation decelerated to 4% (from 7.3%); Specialty Therapies was flat again, with Pelvic Health soft in the sacral-stimulation market while Altaviva scales and Neurovascular still working through the China VBP anniversary (January) and the Vantage recall, both "now mostly behind us." The quarter's real Neuroscience news was regulatory: FDA clearance of Stealth AXiS, the unified AI-planning/robotics/navigation platform, which management expects to contribute to CST "as soon as the fourth quarter."

"Today, navigation, which we pioneered and we lead, drives 70% of U.S. spine procedures… Stealth AXiS fits right into that workflow… You got a better robot with more functionality and then you've got a much, much, much better workflow." — Geoff Martha, Chairman & CEO

Assessment: the workflow argument for Stealth AXiS is genuinely differentiated — spine robotics penetration has lagged navigation precisely because existing robots break the navigated workflow, and a robot that rides the 70%-penetrated navigation installed base (10,000 units) has a structurally easier adoption path than a robot demanding new behavior. We treat the 2.5% print as the last quarter of the old Neuroscience story; Q4 will show whether AXiS and Altaviva can carry the segment back above 4%.

Medical Surgical — Hugo Is Real Now

MedSurg grew 2.7% organic, ahead of expectations. Endoscopy grew 10% (mid-teens esophageal on Nexpowder, EndoFlip 300 adoption); ACM grew 7% on blood-oxygen management and airway access; Surgical grew 1% with strength in energy, wound management, and hernia offset by expected stapling softness. The headline: Hugo received FDA clearance for urology and completed its first U.S. cases at the Cleveland Clinic within weeks — with Touch Surgery installations up over 20% sequentially, past 1,000 systems globally.

Assessment: the speed from clearance to first commercial cases at a marquee academic center is the most encouraging Hugo datapoint to date — flagship-site validation is how robotic franchises seed reference networks. Management was appropriately measured ("you may not move the needle on the Surgical business quite yet"), and we hold our option-value-only stance — but the option is now in the money at the margin: cleared, installed, operating, with hernia (the volume indication) next in the queue.

Diabetes — The U.S. Inflection Has a Date Stamp

Diabetes grew 8.3% organic (15% reported) with double-digit international strength and — the watch item from Q2 — a U.S. sequential acceleration as Simplera Sync and Instinct both launched in December, converting the 35,000-order backlog disclosed in November. The 780G system gained pharmacy-channel availability covering the majority of commercially insured U.S. lives, MiniMed Flex was submitted to the FDA, the Vivera third-generation algorithm began its U.S. pivotal, and the Fit patch pump remains on track for a fall submission. The separation stays "perfectly on track" for completion by end of calendar 2026.

Assessment: every operational box from the November order-book disclosure is checking on schedule. The pharmacy-channel win is underappreciated: CGM economics change materially when sensors flow through pharmacy benefit rather than DME, lowering friction for exactly the type-2 population the new 780G indication opens. MiniMed will IPO into the strongest product cycle in franchise history — which is the point.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: the most expansive and offense-minded call of the fiscal year — management spent its airtime on market-building mechanics, pipeline cadence, and capital deployment rather than defending the quarter, and for the first time framed the portfolio as "four generational growth drivers" each worth over $1 billion. The candor pattern held: the down-margin quarter was neither excused nor spun, and the FY27 dilution items were volunteered with per-month precision. The conspicuous stretch was the insistence on guidance conservatism (reiterate, not raise) while every leading-indicator disclosure pointed up — a deliberate under-promise posture heading into the fiscal year-end print.

1. The Margin Trough Landed As Scheduled — and That's the Point

Adjusted gross margin of 64.9% (−170bp YoY) and operating margin of 24.1% (−210bp YoY) delivered the "down a couple hundred basis points" quarter management pre-announced in November, with tariffs ($93M, 110bp) the largest single component and peak CAS/Diabetes mix the second. Both margins came in "ahead of expectations" internally, full-year gross margin guidance improved 10bp, and Q4 margins were re-confirmed to rise year-over-year with strong sequential improvement.

Assessment: a guided trough that arrives on schedule and slightly shallow is margin credibility, not margin weakness. The structural read-through is unchanged: the 70–80bp/year operational engine (pricing + cost-out) persists beneath the noise, the mix drag peaks now and reverses into FY27 (CAS catheter shift, Diabetes deconsolidation), and tariffs are a step-function that annualizes, not a trend. The Q4 print — margins up YoY while organic holds ~6% — is the proof point that matters next.

2. The FY27 Dilution Ledger: The Real News of the Day

For the first time, management itemized the FY27 bridge's negative entries: tariff carryover of roughly $75M per quarter (~$300M FY27 versus $185M FY26), $0.04–$0.05 of dilution from the CathWorks and Anteris transactions, $0.01–$0.02 per month of dilution between the MiniMed IPO and the final split (the share retirement that drives accretion arrives only at full separation), an interest headwind as near-zero-coupon debt refinances at 3.5–4%, and a now-stabilizing but higher tax rate — partially offset by a 53rd week. High-single-digit FY27 EPS growth was reiterated "all in."

"The Street is sitting at 8.5% EPS growth… it feels like some of the latter items that I mentioned — the sort of temporary dilution that we get from Diabetes and some of the M&A dilution — is maybe not fully embedded in what the Street sees right now." — Thierry Pieton, CFO

Assessment: this is a controlled demolition of the top of the FY27 consensus range, executed three months before guidance is formally set — textbook expectation management from a team that has hit every number it has put in print this year. Critically, every itemized drag is a financing or timing artifact: none of them touches demand, share, pricing, or the operating algorithm. We model FY27 EPS growth at 7–8% on the new ledger (versus 8.5% consensus) and note that the 53rd week and the post-split accretion make FY28 the optically explosive year.

3. CAS: 80% Growth, Four Points of Share, and a Dated $2B Target

Beyond the headline numbers, the disclosures sharpened the competitive map: Medtronic claims double the growth rate of its closest competitor, leading safety and durability data, and a four-player PFA field in which two rivals lead with mapping value propositions (where Medtronic believes its integrated mapping plus superior catheters win) and one leads with catheters (where Medtronic believes Sphere-9's versatility wins). The 50–60% dual-energy utilization stat repositions Sphere-9 from the "niche focal catheter" narrative to the workhorse. Sphere-9 goes to Japan and a VT indication submission lands in 1H CY26; Sphere-360 commercializes in Europe this spring.

Assessment: the share-gain math is now auditable — 4 points in a quarter, in a $13B market, is roughly $130M of quarterly revenue swing, consistent with the reported growth differential. The strategic significance of the dual-energy stat: EP labs are choosing optionality per case, which advantages the only vendor whose single catheter spans both modalities. The $2B-by-1H-FY27 commitment requires no deceleration through mid-year — the most aggressive dated target management has set, and the one we'd track most closely.

4. The Symplicity Funnel: 50x Website Traffic and the Brand Play

The renal denervation market-build produced the quarter's most striking growth-marketing data: direct-to-consumer "Go Beyond" campaign activation drove website visits from ~50,000 in Q2 to ~2.5 million in Q3; 200+ new accounts opened (against a deliberately high bar — five cases plus opt-in); the physician finder reached 150 physicians; and covered lives reached ~100 million, a third of the U.S. population. Management described competitive dynamics as "way better" than any published analyst model and committed to building Symplicity into a brand "synonymous with hypertension management."

"On our direct-to-consumer website around Symplicity… in Q2 we had about 50,000 visits. In Q3, we had 2.5 million visits. So the consumer demand is really spiking here, and we're just getting started… It'll start to — the numbers will be more meaningful in FY '27 for us, the actual revenue… And again, it's very profitable right out of the gate." — Geoff Martha, Chairman & CEO

Assessment: a consumer-demand-led device launch is rare; hypertension is the rare condition where patients self-identify and self-refer. The funnel metrics are leading indicators with real conversion uncertainty — web visits are not procedures — but the 200-account quarter and the "very profitable out of the gate" margin comment (no per-procedure capital, catheter economics) frame the FY27 contribution as high-margin incremental revenue. Management is deliberately not putting revenue numbers out yet; the goalposts promised "as launches mature" are the next disclosure to demand.

5. Hugo Clears, Installs, and Operates — in One Quarter

FDA clearance for urology arrived in-quarter, first U.S. installations and cases completed at the Cleveland Clinic in early February, additional centers scheduled, and a "meaningful step-up in installations around the world" as the U.S. clearance reverberates internationally. The hernia indication — the general-surgery volume driver — is the next planned U.S. expansion, supported by the Enable study that met its endpoints. The fourth-generation software release continues the platform cadence.

Assessment: from a standing start, Hugo's U.S. timeline (clearance → install → first cases at a top-tier academic center in under a month) is faster than we modeled and the right kind of launch — reference-site-first, indication-stacked, ecosystem-attached (Touch Surgery past 1,000 systems). The revenue needle for the $6B Surgical business won't move in FY26 and management said so plainly. What changed is the probability distribution: the robotic-shift headwind that has suppressed Surgical growth for years now has a Medtronic-owned offset with a regulatory green light.

6. Stealth AXiS: The Sleeper Platform the Street Isn't Modeling

Management used unusually strong language — "meaningfully underappreciated… by the investment community" — for the newly cleared spine platform that unifies AI-powered planning, robotics, navigation, and imaging into the navigated workflow that already runs 70% of U.S. spine procedures, on an AiBLE installed base of 10,000 units. Contribution to CST is expected "as soon as the fourth quarter," with cranial and ENT indications planned.

Assessment: we agree with the underappreciation claim directionally. Spine robotics penetration has stalled industry-wide because robots disrupt navigated workflow; a robot that is the navigation system inverts the adoption equation, and Medtronic's enabling-technology share position means AXiS sells into its own installed base. This is a multi-hundred-million-dollar capital cycle hiding inside a segment the Street models at 4–5% — and it lands just as the competitive dynamics in spine enabling tech have, in management's words, "dramatically changed."

7. M&A Activation: CathWorks, Anteris, and "Multiple Shots on Goal"

The promised M&A acceleration produced two transactions: the CathWorks acquisition (FFR-derived coronary physiology imaging, slotted into Coronary & RDN) and a minority investment in Anteris (balloon-expandable TAVR — an entry path into the larger half of the TAVR market where Medtronic doesn't play). Management framed the strategy as venture-to-M&A pipelines, tuck-ins "up to several billion dollars," prioritized toward high-growth must-win markets, with the PFA playbook (organic program + Affera acquisition = multiple shots on goal) as the explicit template.

Assessment: both deals are strategically coherent and financially small — the right profile for a company rebuilding M&A credibility. The Anteris structure (invest, don't acquire) is the more interesting signal: optionality on balloon-expandable TAVR without committing the balance sheet before clinical maturity, mirroring how disciplined acquirers stage entry into binary-risk assets. The $0.04–$0.05 FY27 dilution is the cost of the strategy; the test is whether the Growth Committee keeps the bar at Affera height.

8. Diabetes: The Backlog Converts, the Pharmacy Channel Opens

The U.S. business inflected sequentially as both new sensors launched in December, converting the 35,000-order backlog. The 780G pharmacy-channel agreements covering the majority of commercially insured lives restructure the purchase economics; Flex was submitted to the FDA; Vivera's U.S. pivotal began; Fit remains on track for fall. Separation: "perfectly on track," two-step IPO and split, complete by end of calendar 2026.

Assessment: the franchise enters its IPO year with accelerating U.S. revenue, two fresh sensors, a pharmacy channel, and a three-generation algorithm roadmap — the strongest fundamental posture in a decade. For RemainCo modeling, the IPO-to-split dilution window ($0.01–$0.02/month) makes separation timing a real FY27 EPS variable: a mid-fiscal-year IPO with a quick split minimizes the drag; a stretched window compounds it.

9. Structural Heart: The One Pillar Soft, the Fix Named

Structural Heart grew low-single digits — softer as expected — with European share gains offset by U.S. competitive pressure as Evolut FX+ annualized. A weekend JACC publication showing late mortality catch-up in an old CoreValve cohort drew a direct management response: the valve is no longer commercially available, the technique guidance dates to 2020, and physician communication is underway. The strategic response runs through the Anteris investment and the mitral/tricuspid pipeline.

Assessment: TAVR is the portfolio's only franchise simultaneously losing U.S. momentum and facing adverse clinical headlines — contained, but worth honest weighting. The Evolut platform retains differentiated durability data in smaller annuli and the European trajectory is solid; the U.S. issue is a competitor executing a strong launch cycle into Medtronic's annualizing one. We expect Structural Heart to lag the portfolio through FY27 and treat any balloon-expandable progress as a free option.

Guidance & Outlook

The reiteration disappointed a market trained by two consecutive raise-quarters, but the internal logic is sound: the Q3 revenue beat came from segments management expects to normalize (CRM, ACM), the adverse tax mix carries into Q4, and the launch revenues (Symplicity, Altaviva, Hugo) were deliberately never in the FY26 numbers to begin with. The Q4 setup — ~6% organic against the year's hardest comp, margins inflecting up YoY, tariffs stepping down to $75M — positions the fiscal year-end print as the first quarter where the top line and the margin line accelerate together.

Implied trajectory: FY26 closes at ~5.5–5.7% organic (9M at 5.4%; Q4 ~6%). The FY27 shape: revenue growth accelerating ex-53rd-week (per management's explicit Q&A confirmation), gross margin inflecting on mix reversal, ~$115M incremental tariff headwind, and the M&A/separation dilution items — netting to our 7–8% EPS growth estimate against the "high single digit all in" commitment.

Street at: consensus FY27 EPS growth of ~8.5% needs to absorb roughly $0.06–$0.10 of newly itemized dilution; expect estimate trims of 1–2% — the market took 3.1% off the price for it, which more than discounts the revision.

Guidance style: the under-promise architecture is now explicit — launch revenue excluded, beats decomposed and de-extrapolated, troughs pre-announced, dilution itemized early. Three quarters of evidence say to take the organic guide literally and the EPS guide as a floor.

Analyst Q&A Highlights

Can the FY27 Commitments Survive Tougher Comps and a 1% Surgical Business?

The opening question pressed the two structural soft spots in the FY27 acceleration case: CAS lapping its own monster comps, and Surgical growing just 1% with Hugo's contribution still nascent. Management's answer enumerated the breadth argument — CAS continuing, Symplicity and Altaviva kicking in from Q4, CST inflecting on Stealth AXiS, Neurovascular on new products and comp relief — while the CFO walked the EPS bridge components and, unprompted, disclosed the full dilution ledger.

Q: "Obviously, CAS is starting to hit tougher comps and this quarter, Surgical is only growing 1%. So I'm just trying to think about how you get that business accelerating with Hugo and just like the commitment to be able to deliver on the commitments that you've kind of laid out for FY '27?"
— Travis Steed, BofA Securities

A: "We'll have the carryover from the tariffs settlement going into next year… about $75 million per quarter… around $300 million… the Diabetes deal, we fully expect the deal to be accretive. But between the moment we do the IPO and the moment we do the split, you should expect some dilution to the tune of $0.01 to $0.02 per month… And we've also embedded in the guidance $0.04 to $0.05 of dilution coming from M&A activity… we're committed to the guidance."
— Thierry Pieton, CFO

Assessment: the question asked about growth and got an answer about dilution — because management wanted the dilution items on the record now, on its own terms. The growth half of the answer (breadth: CRM, PVH stepping up in Q3; CST, Neurovascular next; RDN/Altaviva/Hugo in FY27) is actually the stronger case, and it went underpriced in the day's reaction.

What Goalposts Should Investors Use for the RDN and Altaviva Launches?

Asked how the Street should track two launches whose revenues aren't yet disclosed, management committed to publishing more concrete goalposts as the launches mature and, in the meantime, offered the leading-indicator set: 500+ physicians trained on Altaviva, 200+ new RDN accounts (against the five-case-plus-opt-in bar), 150 physicians in the finder, and ~100 million covered lives.

Q: "How should we monitor the progress? Are there any goalposts that we can look forward to in tracking the launch curves for RDN and Altaviva?"
— Vijay Kumar, Evercore ISI

A: "We'll start to lay out more concrete goalposts as we go forward… this quarter, we opened over 200 new accounts, our physician finder's up to 150 physicians. And remember… it's a high bar to get in. You have to do 5 cases and plus opt-in… for RDN, we're already up to like 100 million covered lives, which is about 1/3 of the population here in the U.S."
— Geoff Martha, Chairman & CEO

Assessment: the leading indicators are unusually concrete for a pre-revenue launch narrative, and the five-case account bar means the 200-account number represents ~1,000+ completed procedures minimum in the quarter from new accounts alone — the first triangulable volume signal. The promised goalposts (we'd expect procedure counts or revenue disclosure by the Q4 or Q1 print) are now a management commitment on the record.

Can 80% CAS Growth Sustain Through the $2B Target Window?

A precise modeling question: hitting $2B trailing CAS revenue by 1H FY27 appears to require sustaining ~80% growth for two more quarters even as the Affera U.S. launch laps. Management endorsed the market-growth premise (~20% now, high-teens in FY27, strong double-digit thereafter), confirmed Q4 sustains the growth, declined to guide beyond, and laid out the competitive positioning against all three PFA rivals.

Q: "How are you thinking about the EP market growth in calendar year '26, and your CAS growth going forward now that you're lapping the Affera U.S. launch? I think to achieve the trailing 12-month $2 billion goal, it looks like your CAS growth has to kind of sustain about 80% in the next 2 quarters. Is that directionally accurate?"
— Larry Biegelsen, Wells Fargo Securities

A: "We agree with you on the market growth… of around 20%… for our fiscal '27, we think it's going to be at least high teens and thereafter, a strong double-digit market. In terms of our business growth, we do see it sustaining here in Q4… I know initially our competitor here did a pretty good job of putting out a narrative that Sphere-9 was more of a niche. And I think… that's proven not to be true."
— Geoff Martha, Chairman & CEO

Assessment: management neither confirmed nor walked back the implied ~80%-for-two-more-quarters math — it confirmed Q4 and stopped. We read the $2B/1H-FY27 target as achievable with deceleration to ~50–60% by then, given the trailing-twelve-month construction. The competitive rebuttal of the "niche catheter" narrative, backed by the 50–60% dual-energy stat, was the most pointed competitive moment of the year's calls.

Tuck-Ins or Big Deals? The Capital Allocation Frame

Against a backdrop of large-scale medtech consolidation elsewhere, management drew its line clearly: tuck-ins and close adjacencies — which "can get up to several billion dollars" — in meaningful number across the portfolio, prioritized toward high-growth must-win markets, with deliberate multiple-shots-on-goal redundancy in critical categories.

Q: "There's a lot of other companies doing very large deals in the space. I'm just trying to work out directionally, do you guys feel still more that it's kind of bolt-on M&A, technology tuck-ins, that kind of things relative to larger deals?"
— Patrick Wood, Morgan Stanley

A: "We are focused on more like what we would define as tuck-in deals. They can get up to several billion dollars. But tuck-in, in or a close adjacency to our existing business and a number of them… in some cases, maybe having multiple shots on goal, like we did with Pulsed Field Ablation, right? We did an organic program, we went out and got Affera."
— Geoff Martha, Chairman & CEO

Assessment: "several billion dollars," plural, "a number of them" — the envelope is wider than the bolt-on label suggests. The multiple-shots-on-goal doctrine explains Anteris-as-investment and predicts similar staged entries elsewhere (we'd watch mitral/tricuspid and neurovascular thrombectomy). The discipline evidence so far: two small, strategic, dilution-disclosed deals. So far, so Affera.

The FY27 EPS Bridge, Component by Component

The most quantitative exchange of the call asked for the high-single-digit drivers and whether the Street's 8.5% is the right midpoint. The CFO's answer was a full P&L walk: leverage from accelerating growth, gross margin lift from CAS catheter mix and Diabetes deconsolidation, SG&A leverage with G&A savings outrunning launch investment, interest and tax headwinds below the line, and the explicit flag that Street numbers may not embed the Diabetes-window and M&A dilution.

Q: "How do you think about getting to the high single-digit EPS growth?… the Street is sitting at 8.5% EPS growth… Do you think the Street at 8.5%, is that a good midpoint of the range to start here?"
— Robbie Marcus, JPMorgan

A: "Once that [Diabetes] business goes away, it will give us a natural lift from a gross margin perspective… net-net, the SG&A line will provide leverage… we'll continue to have a little bit of a headwind on the interest line because we're refinancing debt that was contracted almost at 0%… with debt that's now at sort of 3.5%, 4%… it feels like some of the latter items… [are] maybe not fully embedded in what the Street sees right now."
— Thierry Pieton, CFO

Assessment: the most transparent FY27 pre-guide any large-cap medtech has offered this cycle. The component-level honesty raises confidence in the parts of the bridge management controls (mix, SG&A, COGS) precisely because the parts it doesn't control (tariffs, rates, tax) were conceded without prompting. Cut FY27 estimates by the disclosed items and hold the operating assumptions — that's the instruction, and we're taking it.

When Does the CAS Capital-to-Catheter Mix Turn?

Asked when the capital-heavy mix normalizes and where the mapper-constrained center-opening runway stands, the CFO reframed the dilution as desirable for as long as possible — installed-base building — while dating the inflection: second half of FY27, with CAS driving gross margin improvement year-over-year as early as FY27.

Q: "You mentioned generator sales are kind of a headwind to gross margins at this point… If you could give us a sense of when that starts to normalize? And then also in terms of the runway… any sense of where you are in that continuum through the academic centers or into the general centers in the U.S.?"
— Matt Miksic, Barclays

A: "It's almost a good problem to have. So I hope it turns around as late as possible because as we're building the installed base, it's always going to be good news going forward. That being said, I think you'll start to see an inflection in the second half of next year… year-over-year, CAS is going to drive gross margin improvement as early as '27."
— Thierry Pieton, CFO

Assessment: "I hope it turns around as late as possible" is the correct way to think about a razor-and-blade build-out, and the dated inflection (2H FY27) gives the model a checkpoint. The CEO's companion comment — still "relatively early" in penetrating high-volume academic centers — implies the capital wave has quarters to run, which is bullish for the duration of the share grab and the depth of the eventual catheter annuity.

What Market Development Actually Means for Renal Denervation

A question informed by referring-physician checks — reporting surging patient inquiries — asked what building the RDN market concretely involves and pressed for any directional numbers. The answer detailed the apparatus: referral-pathway construction from primary care and hypertension specialists into procedural sites, health-economics/coding/billing support teams, the 50x web-traffic spike, and the long-term Symplicity brand-building investment.

Q: "We've talked to some referring physicians who've been involved in renal denervation since the very beginning, and she sounds like she's getting a lot of calls from folks. I'm just curious what goes into actually developing this market… And if you could give any color on actual numbers to date even directionally?"
— Danielle Antalffy, UBS

A: "All the initial foundational elements have all been like the chips have turned over green… The commercial payers are falling in line and the competitive dynamics are way better than we thought… the numbers will be more meaningful in FY '27 for us, the actual revenue… And again, it's very profitable right out of the gate."
— Geoff Martha, Chairman & CEO

Assessment: third-party channel checks corroborating patient pull is exactly the kind of independent validation a pre-revenue launch narrative needs. The "very profitable right out of the gate" comment matters for the FY27 model — RDN revenue arrives without a capital-placement margin drag, the opposite of the CAS pattern. The refusal to give numbers "even directionally" keeps the launch optionality unpriced.

What They're NOT Saying

1. Adjusted EPS declined year-over-year and no one said the words: $1.36 versus $1.39 is a 2% decline — the first of the fiscal year — absent from the release's bullet points, which lead with growth records. The decline was guided and is transition-mechanical, but the asymmetry between how beats and declines get framed is worth noticing.
2. The raise streak ended quietly: after two consecutive guide-raises, "reiterate" arrived without acknowledgment of the pattern break. The stated reasons (CRM/ACM normalization, tax carry) are credible; the unstated one — keeping Q4 expectations beatable ahead of the FY27 guide — fits the under-promise architecture too well to ignore.
3. RDN and Altaviva revenues remain undisclosed: two launches described as generational, with funnel metrics broadcast at 50x amplification, still report zero revenue numbers. The leading indicators are real; so is the fact that conversion rates from web visits to procedures are unknowable from outside.
4. Hugo has no U.S. order book, system count, or pricing disclosure: "first cases completed" and "more scheduled this week" is the entire quantitative U.S. disclosure. The international business remains numberless after four years. The Q4 print should be pressed for installed-base figures now that the U.S. launch is live.
5. Structural Heart's U.S. share loss is unquantified: "some competitive pressure" covers what peer reporting suggests is a meaningful TAVR share shift. The JACC late-mortality publication response was procedural (old valve, old technique) rather than clinical (no new data offered). This franchise's disclosures are noticeably thinner than its problems.
6. The 53rd week is inside the FY27 "high single digit": management confirmed organic growth accelerates excluding the extra week, but the EPS commitment is "all in" — meaning roughly 1.5–2 points of the FY27 EPS growth comes from the calendar. The quality-adjusted commitment is mid-to-high single digit.
7. No update on Elliott or the Investor Day: second consecutive call without a governance progress report, and the "mid-calendar 2026" Investor Day — now roughly four months away — has no announced date. The new long-term targets promised there will land either just before or alongside the FY27 guide; the sequencing is becoming consequential.

Market Reaction

• Pre-print setup: MDT entered the print at $99.49 (Friday close; Monday was Presidents Day), up ~25% over the trailing twelve months, having consolidated in a $99–103 band since the November breakout through $100. The stock had drifted ~2.5% lower in the pre-print week — positioning was cautious into a quarter pre-announced as the margin trough.
• Day-of session: the stock gapped down ~3.6% at the open to $95.88 and closed at $96.41, −3.1% versus the prior close, on 17.4M shares (~1.8x average) — giving back the November breakout level but holding well above the pre-Q2 base in the mid-$90s.

The decomposition of the decline matters for what happens next. The margin compression cannot explain it — it was guided three months ago to the basis point. The guidance reiteration explains some — a market conditioned by two raises extrapolated a third. But the FY27 dilution ledger explains most: the CFO told the Street, in effect, that its 8.5% EPS growth number is 1–2 points too high, and the stock repriced by approximately that amount against the out-year multiple. That is an estimate-revision trade, not a thesis-revision trade — nothing in the quarter challenged demand, share trajectory, launch progress, or the operating algorithm.

We flagged this exact setup in our November note: "a stock that just broke out above $100 on acceleration enthusiasm meeting a deliberately soft-optics quarter is a recipe for post-print volatility that has nothing to do with the thesis — a buying opportunity if the organic number holds ~5.5%." The organic number came in at 6.0%. The framework holds; the entry improved.

Street Perspective

Debate: Was the Sell-Off Signal or Noise?

Bull view: every component of the decline was either pre-announced (margins, tariffs) or housekeeping (dilution itemization); the operating quarter — 6% organic, 10-quarter record, all four growth drivers cleared — was the strongest of the cycle, and a 3% discount for a 1–2% estimate trim overshoots.

Bear view: a company promising acceleration just printed down EPS, declined to raise despite beating, and pre-loaded next year with $300M of tariffs, deal dilution, and a separation drag — the "telegraphed trough" framing conveniently excuses a year where earnings simply aren't growing while the multiple already re-rated.

Our take: noise, with one fair bear point embedded: FY26 is indeed a sub-3% EPS growth year all-in, and the re-rating since August has been paid against FY27 promises. But the bear case requires the FY27 bridge to fail on its operating components, and every observable input (mix inflection dated, SG&A leverage delivered, pricing holding, launches clearing gates early) is tracking. We'd rather own the estimate-trim discount than fade it.

Debate: Does the CAS Deceleration Glide Path Threaten the Story?

Bull view: even decelerating from 80% to 40–50% through FY27, CAS adds 250–300bp to consolidated growth annually, the catheter-mix shift turns it gross-margin accretive, and Sphere-360's European spring launch plus Japan and VT expansion reload the growth stack before the U.S. comps fully bite.

Bear view: the EP market's 20% growth moderates to high-teens by management's own admission, four players are now shipping PFA, the easy cryo-conversion volume is largely captured, and a franchise priced for 80% growth that prints 45% will feel like a miss regardless of the math.

Our take: the $2B-by-1H-FY27 target is the referendum, and the trailing-twelve-month construction means it survives meaningful deceleration. The asymmetric variable is Sphere-360 — a successful single-shot launch extends the share gains into the segment where the incumbent is strongest; its European commercial reception this spring is the next datapoint. We model glide-path deceleration and still get the date.

Debate: Is the M&A Pivot Discipline or Drift?

Bull view: two strategically surgical transactions, dilution disclosed to the penny before close, the Affera template explicitly invoked, and a venture pipeline staging future entries — this is what credible, board-supervised capital deployment looks like after years of inactivity.

Bear view: "tuck-ins up to several billion dollars," "a number of them," "multiple shots on goal" — the vocabulary is expanding faster than the proof, $0.04–$0.05 of dilution arrived before any revenue did, and activist-era companies habitually buy growth when organic acceleration needs insurance.

Our take: two data points favor discipline; the vocabulary favors vigilance. The genuine test arrives when a several-billion-dollar target in a must-win market gets priced against the Growth Committee's bar. Until then, the deals done are the deals we'd have wanted done — CathWorks digitizes the RDN/coronary workflow it just built a market for, and Anteris stages TAVR optionality without balance-sheet commitment.

Model Update Needed

Valuation impact: at $96.41, MDT trades at ~17.1x the FY26 guide midpoint and ~15.8–16.0x our trimmed FY27 EPS (~$6.05), with a ~2.9% dividend yield. The 3% repricing fully absorbs the FY27 estimate revision the CFO engineered; what it does not price is any revenue from Symplicity, Altaviva, Hugo, or Stealth AXiS beyond modest assumptions — four cleared, launched growth vectors. Our $112–$120 framework holds on trimmed-FY27 earnings power at 18.5–19.5x; the risk/reward at ~$96 is better than it was at $100.80 in November with strictly more thesis confirmation in hand.

Thesis Scorecard Post-Earnings

Overall: thesis intact and operationally strengthened — the sell-off was an estimate-revision event management deliberately engineered early, not a fundamental disappointment. Three consecutive quarters of organic acceleration with all four generational drivers now cleared is a better fact set than either prior quarter offered.

Action: maintain Outperform. Watch items for Q4 (early June): margins inflecting up YoY as guided (the proof point for the FY27 algorithm), first RDN/Altaviva goalposts or revenue disclosure, the FY27 guide formally bracketing high-single-digit EPS, CAS holding ~80% against the hardest comp, and MiniMed IPO timing specifics. A Q4 that delivers margins-up-plus-6%-organic resolves the only honest bear argument left.